Abstract: A compute fabric includes, in part: a multitude of compute tiles disposed in a memory block, a networking circuit coupled to the compute tiles and adapted to enable communication between the compute tiles and further to enable the compute tiles to communicate with a system external to the compute fabric; and controller configured to control the of compute tiles. Each compute tiles includes, in part, a multitude of multiplying bit-cells (MBC) disposed along M rows and N columns, where M an N are integers greater than one. Each MBC is configured to: multiply a first bit by a second bit to generate a multiplication value; convert the multiplication value to a charge; and store the charge in a capacitor disposed in the MBC.

Abstract: In an embodiment, a method facilitates battery replacement in a smart-home system. The method includes measuring, by one or more smart-home devices, at least one characteristic of a first battery in one of the smart-home devices, and determining from the at least one characteristic, whether replacement of the first battery is warranted. If replacement is warranted, the method sends an electronic order to a supplier for a replacement battery. The method further includes reading, by one or more of the smart-home devices, a machine readable code that accompanies a shipment of the replacement battery, embodying information from which an identity of the first smart-home device can be determined; determining, based at least in part on the information, a location of the first smart-home device; and providing, by one or more of the smart-home devices, visual and/or audible information to guide a user to the first smart-home device.

Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3, 5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.

Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.

Abstract: A method for determining and/or engineering photosynthetic mutant algal strains comprising: (A) pre-screening wild-type or parent strains to select for photosynthetic efficiency; (B) cause genetic mutations in the group of wild-type and/or parent strains from pre-screening (A) to form genetic mutant strains; (C) screening the genetic mutant strains for photosynthetic efficiency in mass cultures; and (D) further screening the genetic mutants resulting from screening (C) by measuring biomass productivity to select strains having relatively high biomass/lipid/starch productivity.

Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.

Abstract: In an embodiment, a method facilitates battery replacement in a smart-home system. The method includes measuring, by one or more smart-home devices, at least one characteristic of a first battery in one of the smart-home devices, and determining from the at least one characteristic, whether replacement of the first battery is warranted. If replacement is warranted, the method sends an electronic order to a supplier for a replacement battery. The method further includes reading, by one or more of the smart-home devices, a machine readable code that accompanies a shipment of the replacement battery, embodying information from which an identity of the first smart-home device can be determined; determining, based at least in part on the information, a location of the first smart-home device; and providing, by one or more of the smart-home devices, visual and/or audible information to guide a user to the first smart-home device.

Abstract: The present invention is directed to a pure enantiomer of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, in particular, (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-y1)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone. The present invention is also directed a crystal structure of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a pharmaceutical composition of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, a method of inhibiting PDE10 with (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, and a process and particular individual intermediates used in the production of (S)-1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone.

Abstract: Systems and methods are provided to select strains of algal cells for biomass accumulation. Based on synthetic algae sample trajectories, an illumination profile is developed. Strains of algal cells co-cultured in a vessel can then be exposed to the illumination profile under controlled conditions. Properties of algae can be measured and superior strains selected for further cultivation and/or study.

Abstract: A method for determining and/or engineering photosynthetic mutant algal strains comprising: (A) pre-screening wild-type or parent strains to select for photosynthetic efficiency; (B) cause genetic mutations in the group of wild-type and/or parent strains from pre-screening (A) to form genetic mutant strains; (C) screening the genetic mutant strains for photosynthetic efficiency in mass cultures; and (D) further screening the genetic mutants resulting from screening (C) by measuring biomass productivity to select strains having relatively high biomass/lipid/starch productivity.

Abstract: This invention is related to methods of extracting and measuring the presence of BMP in DBM. In particular, by omitting the final dialysis step, the measured BMP yield can be dramatically increased.